|Bid||36.00 x 1300|
|Ask||44.50 x 1000|
|Day's Range||39.23 - 40.64|
|52 Week Range||27.85 - 54.45|
|Beta (3Y Monthly)||3.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 2, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.33|
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Isaac Ciechanover, M.D., plans to step down as the Company’s President and Chief Executive Officer. Dr. Ciechanover will remain in his role as President and CEO until the earlier of the appointment of his successor or June 30, 2019. “Isaac is a visionary founder and CEO who started Atara in honor of his mother to transform the lives of patients with serious medical conditions,” said Carol G. Gallagher, Pharm.
Initial results from ongoing Phase 1 study for mesothelin-targeted CAR T support activity and safety in patients with advanced solid tumors Atara’s next-generation CAR T.
We can judge whether Atara Biotherapeutics Inc (NASDAQ:ATRA) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best […]
Second EBV‑associated solid tumor with encouraging responses to tab-cel®Tab-cel® safety appears consistent with a favorable risk profile and previous observationsResults were.
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.29. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...